Eliem Therapeutics (NASDAQ:ELYM) Trading Down 6.8% – What’s Next?

Eliem Therapeutics, Inc. (NASDAQ:ELYM)’s stock price fell 6.8% on Tuesday . The stock traded as low as $6.4750 and last traded at $6.54. 307,447 shares traded hands during trading, a decline of 37% from the average session volume of 486,688 shares. The stock had previously closed at $7.02.

Eliem Therapeutics Stock Performance

The stock’s 50 day simple moving average is $6.05 and its 200-day simple moving average is $3.83. The firm has a market cap of $194.58 million, a price-to-earnings ratio of -12.34 and a beta of -0.39.

Eliem Therapeutics Company Profile

Eliem Therapeutics, Inc is a clinical‐stage biotechnology company focused on the development of novel therapeutics for the treatment of neurological and neuropsychiatric disorders. The company’s scientific approach is centered on proprietary peptide and small‐molecule drug candidates designed to modulate central nervous system pathways. By leveraging targeted delivery and receptor‐specific activity, Eliem seeks to address unmet medical needs in areas such as pain management, spasticity and other debilitating sequelae of spinal cord injury.

The company’s most advanced program, ELI-200, is being investigated as a potential treatment for spasticity and neuropathic pain associated with spinal cord injury.